Quince Therapeutics (NASDAQ:QNCX) Receives Buy Rating from D. Boral Capital

Quince Therapeutics (NASDAQ:QNCX - Get Free Report)'s stock had its "buy" rating reaffirmed by equities researchers at D. Boral Capital in a report issued on Thursday,Benzinga reports. They presently have a $12.00 price objective on the stock.

Several other equities research analysts also recently issued reports on QNCX. RODMAN&RENSHAW upgraded Quince Therapeutics to a "strong-buy" rating in a research report on Tuesday, October 29th. Rodman & Renshaw began coverage on Quince Therapeutics in a research note on Tuesday, October 29th. They issued a "buy" rating and a $11.00 target price for the company. Brookline Capital Management initiated coverage on Quince Therapeutics in a report on Wednesday, December 18th. They set a "buy" rating and a $9.00 target price for the company. Maxim Group initiated coverage on shares of Quince Therapeutics in a report on Thursday, November 7th. They issued a "buy" rating and a $6.00 price target on the stock. Finally, EF Hutton Acquisition Co. I raised shares of Quince Therapeutics to a "strong-buy" rating in a research note on Tuesday, October 22nd. Four research analysts have rated the stock with a buy rating and two have given a strong buy rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of "Buy" and a consensus target price of $9.50.

Quince Therapeutics Stock Performance

Shares of NASDAQ QNCX traded up $0.01 during trading on Thursday, reaching $1.88. 85,122 shares of the stock traded hands, compared to its average volume of 230,928. The company has a debt-to-equity ratio of 0.33, a current ratio of 9.53 and a quick ratio of 9.53. The stock has a market capitalization of $82.72 million, a P/E ratio of -1.52 and a beta of 0.74. Quince Therapeutics has a 52-week low of $0.51 and a 52-week high of $2.45. The company has a 50-day moving average of $1.77 and a 200-day moving average of $1.09.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in Quince Therapeutics stock. Geode Capital Management LLC raised its stake in Quince Therapeutics, Inc. (NASDAQ:QNCX - Free Report) by 24.2% during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 339,125 shares of the company's stock after buying an additional 66,170 shares during the period. Geode Capital Management LLC owned about 0.78% of Quince Therapeutics worth $263,000 at the end of the most recent quarter. Hedge funds and other institutional investors own 30.75% of the company's stock.

Quince Therapeutics Company Profile

Quince Therapeutics, Inc, a biopharmaceutical company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases. The company's lead asset candidature comprises EryDex for the treatment of rare pediatric neurodegenerative disease, including A-T, an inherited autosomal recessive neurodegenerative and immunodeficiency disorder caused by mutations in ATM gene.